Dexmetomidine With Erector Spinae Plane Block in Cholecystectomy

• Status: Recruiting
• Trial end date: 2022-07-10
• Target enrollment: 0
• Participant gender: All

Summary

Sixty patients scheduled for elective laparoscopic cholecystectomy will be randomly assigned using sealed envelope into two equal groups (30 patients each).

Group 1: will receive bilateral ESP block with injection of 20 ml of 0.25% Bupivacaine in each site of injection .

Group 2: will receive bilateral ESP block with injection of 18ml of 0.25% Bupivacaine plus 2ml dexmedetomidine 0.5 ug /kg in each site of injection .

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tanta University
• Treatments: Bupivacaine; Dexmedetomidine

Criteria

• Patients undergoing elective laparoscopic cholecystectomy

• aged 18-65 years old

• ASA physical status I or II.

Exclusion Criteria:

• patients who refuse to give written informed consent

• sever respiratory or cardiac disorder

• coagulopathy

• local infection at injection site

• spine or chest wall deformity

• patients with known allergy to the drugs used